266 related articles for article (PubMed ID: 33073585)
1. The complicated role of mitochondria in the podocyte.
Gujarati NA; Vasquez JM; Bogenhagen DF; Mallipattu SK
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F955-F965. PubMed ID: 33073585
[TBL] [Abstract][Full Text] [Related]
2. Reduced Lon protease 1 expression in podocytes contributes to the pathogenesis of podocytopathy.
Gong W; Song J; Liang J; Ma H; Wu W; Zhang Y; Yang L; Huang S; Jia Z; Zhang A
Kidney Int; 2021 Apr; 99(4):854-869. PubMed ID: 33181155
[TBL] [Abstract][Full Text] [Related]
3. Biofactors regulating mitochondrial function and dynamics in podocytes and podocytopathies.
Hejazian SM; Ardalan M; Hosseiniyan Khatibi SM; Rahbar Saadat Y; Barzegari A; Gueguen V; Meddahi-Pellé A; Anagnostou F; Zununi Vahed S; Pavon-Djavid G
J Cell Physiol; 2023 Oct; 238(10):2206-2227. PubMed ID: 37659096
[TBL] [Abstract][Full Text] [Related]
4. Nephrinuria and podocytopathies.
Kostovska I; Trajkovska KT; Topuzovska S; Cekovska S; Labudovic D; Kostovski O; Spasovski G
Adv Clin Chem; 2022; 108():1-36. PubMed ID: 35659057
[TBL] [Abstract][Full Text] [Related]
5. Autophagy and podocytopathy.
Ponticelli C; Moroni G; Reggiani F
Nephrol Dial Transplant; 2023 Aug; 38(9):1931-1939. PubMed ID: 36708169
[TBL] [Abstract][Full Text] [Related]
6. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
7. Podocyte energy metabolism and glomerular diseases.
Imasawa T; Rossignol R
Int J Biochem Cell Biol; 2013 Sep; 45(9):2109-18. PubMed ID: 23806869
[TBL] [Abstract][Full Text] [Related]
8. CD73 Overexpression in Podocytes: A Novel Marker of Podocyte Injury in Human Kidney Disease.
Popovic ZV; Bestvater F; Krunic D; Krämer BK; Bergner R; Löffler C; Hocher B; Marx A; Porubsky S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299260
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury.
Su M; Dhoopun AR; Yuan Y; Huang S; Zhu C; Ding G; Liu B; Yang T; Zhang A
Am J Physiol Renal Physiol; 2013 Aug; 305(4):F520-31. PubMed ID: 23761667
[TBL] [Abstract][Full Text] [Related]
10. [The role of podocyte injury in chronic kidney disease].
Asanuma K
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(1):26-36. PubMed ID: 25765686
[TBL] [Abstract][Full Text] [Related]
11. Fn14 in podocytes and proteinuric kidney disease.
Sanchez-Niño MD; Poveda J; Sanz AB; Mezzano S; Carrasco S; Fernandez-Fernandez B; Burkly LC; Nair V; Kretzler M; Hodgin JB; Ruiz-Ortega M; Selgas R; Egido J; Ortiz A
Biochim Biophys Acta; 2013 Dec; 1832(12):2232-43. PubMed ID: 23999007
[TBL] [Abstract][Full Text] [Related]
12. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.
Daehn I; Casalena G; Zhang T; Shi S; Fenninger F; Barasch N; Yu L; D'Agati V; Schlondorff D; Kriz W; Haraldsson B; Bottinger EP
J Clin Invest; 2014 Apr; 124(4):1608-21. PubMed ID: 24590287
[TBL] [Abstract][Full Text] [Related]
13. Mpv17 in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis in vivo and in vitro.
Casalena G; Krick S; Daehn I; Yu L; Ju W; Shi S; Tsai SY; D'Agati V; Lindenmeyer M; Cohen CD; Schlondorff D; Bottinger EP
Am J Physiol Renal Physiol; 2014 Jun; 306(11):F1372-80. PubMed ID: 24598802
[TBL] [Abstract][Full Text] [Related]
14. Dysfunction of the PGC-1α-mitochondria axis confers adriamycin-induced podocyte injury.
Zhu C; Xuan X; Che R; Ding G; Zhao M; Bai M; Jia Z; Huang S; Zhang A
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1410-7. PubMed ID: 24808537
[TBL] [Abstract][Full Text] [Related]
15. Protective role of cyclosporine A and minocycline on mitochondrial disequilibrium-related podocyte injury and proteinuria occurrence induced by adriamycin.
Guan N; Ren YL; Liu XY; Zhang Y; Pei P; Zhu SN; Fan Q
Nephrol Dial Transplant; 2015 Jun; 30(6):957-69. PubMed ID: 25646018
[TBL] [Abstract][Full Text] [Related]
16. Could Autophagic Exhaustion Be a Final Common Pathway for Podocytopathy in FSGS?
Venkatachalam MA
J Am Soc Nephrol; 2015 May; 26(5):999-1001. PubMed ID: 25406340
[No Abstract] [Full Text] [Related]
17. Sirtuins as novel pharmacological targets in podocyte injury and related glomerular diseases.
Liu T; Yang L; Mao H; Ma F; Wang Y; Li S; Li P; Zhan Y
Biomed Pharmacother; 2022 Nov; 155():113620. PubMed ID: 36122519
[TBL] [Abstract][Full Text] [Related]
18. A Review of Podocyte Biology.
Garg P
Am J Nephrol; 2018; 47 Suppl 1():3-13. PubMed ID: 29852492
[TBL] [Abstract][Full Text] [Related]
19. Targeting podocyte-associated diseases.
Leeuwis JW; Nguyen TQ; Dendooven A; Kok RJ; Goldschmeding R
Adv Drug Deliv Rev; 2010 Nov; 62(14):1325-36. PubMed ID: 20828590
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury.
Arif E; Solanki AK; Srivastava P; Rahman B; Fitzgibbon WR; Deng P; Budisavljevic MN; Baicu CF; Zile MR; Megyesi J; Janech MG; Kwon SH; Collier J; Schnellmann RG; Nihalani D
Kidney Int; 2019 Sep; 96(3):656-673. PubMed ID: 31262488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
